Global Antidiabetic SGLT-2 Inhibitor Market Insights and Forecast to 2028

Global Antidiabetic SGLT-2 Inhibitor Market Insights and Forecast to 2028

Table of Contents
1 Study Coverage
1.1 Antidiabetic SGLT-2 Inhibitor Product Introduction
1.2 Market by Type
1.2.1 Global Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Canagliflozin
1.2.3 Empagliflozin
1.2.4 Dapagliflozin
1.2.5 Other
1.3 Market by Application
1.3.1 Global Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Antidiabetic SGLT-2 Inhibitor Sales Estimates and Forecasts 2017-2028
2.2 Global Antidiabetic SGLT-2 Inhibitor Revenue Estimates and Forecasts 2017-2028
2.3 Global Antidiabetic SGLT-2 Inhibitor Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Antidiabetic SGLT-2 Inhibitor Sales by Region
2.4.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Region (2017-2022)
2.4.2 Global Sales Antidiabetic SGLT-2 Inhibitor by Region (2023-2028)
2.5 Global Antidiabetic SGLT-2 Inhibitor Revenue by Region
2.5.1 Global Antidiabetic SGLT-2 Inhibitor Revenue by Region (2017-2022)
2.5.2 Global Antidiabetic SGLT-2 Inhibitor Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Manufacturers
3.1.1 Global Top Antidiabetic SGLT-2 Inhibitor Manufacturers by Sales (2017-2022)
3.1.2 Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Antidiabetic SGLT-2 Inhibitor in 2021
3.2 Global Antidiabetic SGLT-2 Inhibitor Revenue by Manufacturers
3.2.1 Global Antidiabetic SGLT-2 Inhibitor Revenue by Manufacturers (2017-2022)
3.2.2 Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Antidiabetic SGLT-2 Inhibitor Revenue in 2021
3.3 Global Antidiabetic SGLT-2 Inhibitor Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Antidiabetic SGLT-2 Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Antidiabetic SGLT-2 Inhibitor Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Type
4.1.1 Global Antidiabetic SGLT-2 Inhibitor Historical Sales by Type (2017-2022)
4.1.2 Global Antidiabetic SGLT-2 Inhibitor Forecasted Sales by Type (2023-2028)
4.1.3 Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2017-2028)
4.2 Global Antidiabetic SGLT-2 Inhibitor Revenue by Type
4.2.1 Global Antidiabetic SGLT-2 Inhibitor Historical Revenue by Type (2017-2022)
4.2.2 Global Antidiabetic SGLT-2 Inhibitor Forecasted Revenue by Type (2023-2028)
4.2.3 Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type (2017-2028)
4.3 Global Antidiabetic SGLT-2 Inhibitor Price by Type
4.3.1 Global Antidiabetic SGLT-2 Inhibitor Price by Type (2017-2022)
4.3.2 Global Antidiabetic SGLT-2 Inhibitor Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Application
5.1.1 Global Antidiabetic SGLT-2 Inhibitor Historical Sales by Application (2017-2022)
5.1.2 Global Antidiabetic SGLT-2 Inhibitor Forecasted Sales by Application (2023-2028)
5.1.3 Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2017-2028)
5.2 Global Antidiabetic SGLT-2 Inhibitor Revenue by Application
5.2.1 Global Antidiabetic SGLT-2 Inhibitor Historical Revenue by Application (2017-2022)
5.2.2 Global Antidiabetic SGLT-2 Inhibitor Forecasted Revenue by Application (2023-2028)
5.2.3 Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application (2017-2028)
5.3 Global Antidiabetic SGLT-2 Inhibitor Price by Application
5.3.1 Global Antidiabetic SGLT-2 Inhibitor Price by Application (2017-2022)
5.3.2 Global Antidiabetic SGLT-2 Inhibitor Price Forecast by Application (2023-2028)
6 North America
6.1 North America Antidiabetic SGLT-2 Inhibitor Market Size by Type
6.1.1 North America Antidiabetic SGLT-2 Inhibitor Sales by Type (2017-2028)
6.1.2 North America Antidiabetic SGLT-2 Inhibitor Revenue by Type (2017-2028)
6.2 North America Antidiabetic SGLT-2 Inhibitor Market Size by Application
6.2.1 North America Antidiabetic SGLT-2 Inhibitor Sales by Application (2017-2028)
6.2.2 North America Antidiabetic SGLT-2 Inhibitor Revenue by Application (2017-2028)
6.3 North America Antidiabetic SGLT-2 Inhibitor Market Size by Country
6.3.1 North America Antidiabetic SGLT-2 Inhibitor Sales by Country (2017-2028)
6.3.2 North America Antidiabetic SGLT-2 Inhibitor Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Antidiabetic SGLT-2 Inhibitor Market Size by Type
7.1.1 Europe Antidiabetic SGLT-2 Inhibitor Sales by Type (2017-2028)
7.1.2 Europe Antidiabetic SGLT-2 Inhibitor Revenue by Type (2017-2028)
7.2 Europe Antidiabetic SGLT-2 Inhibitor Market Size by Application
7.2.1 Europe Antidiabetic SGLT-2 Inhibitor Sales by Application (2017-2028)
7.2.2 Europe Antidiabetic SGLT-2 Inhibitor Revenue by Application (2017-2028)
7.3 Europe Antidiabetic SGLT-2 Inhibitor Market Size by Country
7.3.1 Europe Antidiabetic SGLT-2 Inhibitor Sales by Country (2017-2028)
7.3.2 Europe Antidiabetic SGLT-2 Inhibitor Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Antidiabetic SGLT-2 Inhibitor Market Size by Type
8.1.1 Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Type (2017-2028)
8.1.2 Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue by Type (2017-2028)
8.2 Asia Pacific Antidiabetic SGLT-2 Inhibitor Market Size by Application
8.2.1 Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Application (2017-2028)
8.2.2 Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue by Application (2017-2028)
8.3 Asia Pacific Antidiabetic SGLT-2 Inhibitor Market Size by Region
8.3.1 Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Region (2017-2028)
8.3.2 Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Antidiabetic SGLT-2 Inhibitor Market Size by Type
9.1.1 Latin America Antidiabetic SGLT-2 Inhibitor Sales by Type (2017-2028)
9.1.2 Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Type (2017-2028)
9.2 Latin America Antidiabetic SGLT-2 Inhibitor Market Size by Application
9.2.1 Latin America Antidiabetic SGLT-2 Inhibitor Sales by Application (2017-2028)
9.2.2 Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Application (2017-2028)
9.3 Latin America Antidiabetic SGLT-2 Inhibitor Market Size by Country
9.3.1 Latin America Antidiabetic SGLT-2 Inhibitor Sales by Country (2017-2028)
9.3.2 Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Market Size by Type
10.1.1 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Type (2017-2028)
10.1.2 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue by Type (2017-2028)
10.2 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Market Size by Application
10.2.1 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Application (2017-2028)
10.2.2 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue by Application (2017-2028)
10.3 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Market Size by Country
10.3.1 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Country (2017-2028)
10.3.2 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Corporation Information
11.1.2 Pfizer Overview
11.1.3 Pfizer Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Pfizer Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Pfizer Recent Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Corporation Information
11.2.2 AstraZeneca Overview
11.2.3 AstraZeneca Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 AstraZeneca Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 AstraZeneca Recent Developments
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Corporation Information
11.3.2 Johnson & Johnson Overview
11.3.3 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Johnson & Johnson Recent Developments
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Corporation Information
11.4.2 GlaxoSmithKline Overview
11.4.3 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 GlaxoSmithKline Recent Developments
11.5 Merck & Co
11.5.1 Merck & Co Corporation Information
11.5.2 Merck & Co Overview
11.5.3 Merck & Co Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Merck & Co Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Merck & Co Recent Developments
11.6 Eli Lilly
11.6.1 Eli Lilly Corporation Information
11.6.2 Eli Lilly Overview
11.6.3 Eli Lilly Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Eli Lilly Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Eli Lilly Recent Developments
11.7 Sanofi
11.7.1 Sanofi Corporation Information
11.7.2 Sanofi Overview
11.7.3 Sanofi Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Sanofi Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Sanofi Recent Developments
11.8 Takeda Pharmaceuticals
11.8.1 Takeda Pharmaceuticals Corporation Information
11.8.2 Takeda Pharmaceuticals Overview
11.8.3 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Takeda Pharmaceuticals Recent Developments
11.9 Novo Nordisk
11.9.1 Novo Nordisk Corporation Information
11.9.2 Novo Nordisk Overview
11.9.3 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Novo Nordisk Recent Developments
11.10 Servier Laboratories
11.10.1 Servier Laboratories Corporation Information
11.10.2 Servier Laboratories Overview
11.10.3 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Servier Laboratories Recent Developments
11.11 Boehringer Ingelheim
11.11.1 Boehringer Ingelheim Corporation Information
11.11.2 Boehringer Ingelheim Overview
11.11.3 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Boehringer Ingelheim Recent Developments
11.12 Bristol-Myers Squibb
11.12.1 Bristol-Myers Squibb Corporation Information
11.12.2 Bristol-Myers Squibb Overview
11.12.3 Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Bristol-Myers Squibb Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Antidiabetic SGLT-2 Inhibitor Industry Chain Analysis
12.2 Antidiabetic SGLT-2 Inhibitor Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Antidiabetic SGLT-2 Inhibitor Production Mode & Process
12.4 Antidiabetic SGLT-2 Inhibitor Sales and Marketing
12.4.1 Antidiabetic SGLT-2 Inhibitor Sales Channels
12.4.2 Antidiabetic SGLT-2 Inhibitor Distributors
12.5 Antidiabetic SGLT-2 Inhibitor Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Antidiabetic SGLT-2 Inhibitor Industry Trends
13.2 Antidiabetic SGLT-2 Inhibitor Market Drivers
13.3 Antidiabetic SGLT-2 Inhibitor Market Challenges
13.4 Antidiabetic SGLT-2 Inhibitor Market Restraints
14 Key Findings in The Global Antidiabetic SGLT-2 Inhibitor Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Canagliflozin
Table 3. Major Manufacturers of Empagliflozin
Table 4. Major Manufacturers of Dapagliflozin
Table 5. Major Manufacturers of Other
Table 6. Global Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Antidiabetic SGLT-2 Inhibitor Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 8. Global Antidiabetic SGLT-2 Inhibitor Sales by Region (2017-2022) & (K Pcs)
Table 9. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region (2017-2022)
Table 10. Global Antidiabetic SGLT-2 Inhibitor Sales by Region (2023-2028) & (K Pcs)
Table 11. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region (2023-2028)
Table 12. Global Antidiabetic SGLT-2 Inhibitor Revenue by Region (2017-2022) & (US$ Million)
Table 13. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Region (2017-2022)
Table 14. Global Antidiabetic SGLT-2 Inhibitor Revenue by Region (2023-2028) & (US$ Million)
Table 15. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Region (2023-2028)
Table 16. Global Antidiabetic SGLT-2 Inhibitor Sales by Manufacturers (2017-2022) & (K Pcs)
Table 17. Global Antidiabetic SGLT-2 Inhibitor Sales Share by Manufacturers (2017-2022)
Table 18. Global Antidiabetic SGLT-2 Inhibitor Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 19. Global Antidiabetic SGLT-2 Inhibitor Revenue Share by Manufacturers (2017-2022)
Table 20. Antidiabetic SGLT-2 Inhibitor Price by Manufacturers (2017-2022) &(USD/Pcs)
Table 21. Global Antidiabetic SGLT-2 Inhibitor Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Antidiabetic SGLT-2 Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antidiabetic SGLT-2 Inhibitor as of 2021)
Table 23. Antidiabetic SGLT-2 Inhibitor Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Antidiabetic SGLT-2 Inhibitor Product Offered
Table 25. Date of Manufacturers Enter into Antidiabetic SGLT-2 Inhibitor Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2017-2022) & (K Pcs)
Table 28. Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2023-2028) & (K Pcs)
Table 29. Global Antidiabetic SGLT-2 Inhibitor Sales Share by Type (2017-2022)
Table 30. Global Antidiabetic SGLT-2 Inhibitor Sales Share by Type (2023-2028)
Table 31. Global Antidiabetic SGLT-2 Inhibitor Revenue by Type (2017-2022) & (US$ Million)
Table 32. Global Antidiabetic SGLT-2 Inhibitor Revenue by Type (2023-2028) & (US$ Million)
Table 33. Global Antidiabetic SGLT-2 Inhibitor Revenue Share by Type (2017-2022)
Table 34. Global Antidiabetic SGLT-2 Inhibitor Revenue Share by Type (2023-2028)
Table 35. Antidiabetic SGLT-2 Inhibitor Price by Type (2017-2022) & (USD/Pcs)
Table 36. Global Antidiabetic SGLT-2 Inhibitor Price Forecast by Type (2023-2028) & (USD/Pcs)
Table 37. Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2017-2022) & (K Pcs)
Table 38. Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2023-2028) & (K Pcs)
Table 39. Global Antidiabetic SGLT-2 Inhibitor Sales Share by Application (2017-2022)
Table 40. Global Antidiabetic SGLT-2 Inhibitor Sales Share by Application (2023-2028)
Table 41. Global Antidiabetic SGLT-2 Inhibitor Revenue by Application (2017-2022) & (US$ Million)
Table 42. Global Antidiabetic SGLT-2 Inhibitor Revenue by Application (2023-2028) & (US$ Million)
Table 43. Global Antidiabetic SGLT-2 Inhibitor Revenue Share by Application (2017-2022)
Table 44. Global Antidiabetic SGLT-2 Inhibitor Revenue Share by Application (2023-2028)
Table 45. Antidiabetic SGLT-2 Inhibitor Price by Application (2017-2022) & (USD/Pcs)
Table 46. Global Antidiabetic SGLT-2 Inhibitor Price Forecast by Application (2023-2028) & (USD/Pcs)
Table 47. North America Antidiabetic SGLT-2 Inhibitor Sales by Type (2017-2022) & (K Pcs)
Table 48. North America Antidiabetic SGLT-2 Inhibitor Sales by Type (2023-2028) & (K Pcs)
Table 49. North America Antidiabetic SGLT-2 Inhibitor Revenue by Type (2017-2022) & (US$ Million)
Table 50. North America Antidiabetic SGLT-2 Inhibitor Revenue by Type (2023-2028) & (US$ Million)
Table 51. North America Antidiabetic SGLT-2 Inhibitor Sales by Application (2017-2022) & (K Pcs)
Table 52. North America Antidiabetic SGLT-2 Inhibitor Sales by Application (2023-2028) & (K Pcs)
Table 53. North America Antidiabetic SGLT-2 Inhibitor Revenue by Application (2017-2022) & (US$ Million)
Table 54. North America Antidiabetic SGLT-2 Inhibitor Revenue by Application (2023-2028) & (US$ Million)
Table 55. North America Antidiabetic SGLT-2 Inhibitor Sales by Country (2017-2022) & (K Pcs)
Table 56. North America Antidiabetic SGLT-2 Inhibitor Sales by Country (2023-2028) & (K Pcs)
Table 57. North America Antidiabetic SGLT-2 Inhibitor Revenue by Country (2017-2022) & (US$ Million)
Table 58. North America Antidiabetic SGLT-2 Inhibitor Revenue by Country (2023-2028) & (US$ Million)
Table 59. Europe Antidiabetic SGLT-2 Inhibitor Sales by Type (2017-2022) & (K Pcs)
Table 60. Europe Antidiabetic SGLT-2 Inhibitor Sales by Type (2023-2028) & (K Pcs)
Table 61. Europe Antidiabetic SGLT-2 Inhibitor Revenue by Type (2017-2022) & (US$ Million)
Table 62. Europe Antidiabetic SGLT-2 Inhibitor Revenue by Type (2023-2028) & (US$ Million)
Table 63. Europe Antidiabetic SGLT-2 Inhibitor Sales by Application (2017-2022) & (K Pcs)
Table 64. Europe Antidiabetic SGLT-2 Inhibitor Sales by Application (2023-2028) & (K Pcs)
Table 65. Europe Antidiabetic SGLT-2 Inhibitor Revenue by Application (2017-2022) & (US$ Million)
Table 66. Europe Antidiabetic SGLT-2 Inhibitor Revenue by Application (2023-2028) & (US$ Million)
Table 67. Europe Antidiabetic SGLT-2 Inhibitor Sales by Country (2017-2022) & (K Pcs)
Table 68. Europe Antidiabetic SGLT-2 Inhibitor Sales by Country (2023-2028) & (K Pcs)
Table 69. Europe Antidiabetic SGLT-2 Inhibitor Revenue by Country (2017-2022) & (US$ Million)
Table 70. Europe Antidiabetic SGLT-2 Inhibitor Revenue by Country (2023-2028) & (US$ Million)
Table 71. Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Type (2017-2022) & (K Pcs)
Table 72. Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Type (2023-2028) & (K Pcs)
Table 73. Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue by Type (2017-2022) & (US$ Million)
Table 74. Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue by Type (2023-2028) & (US$ Million)
Table 75. Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Application (2017-2022) & (K Pcs)
Table 76. Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Application (2023-2028) & (K Pcs)
Table 77. Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue by Application (2017-2022) & (US$ Million)
Table 78. Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue by Application (2023-2028) & (US$ Million)
Table 79. Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Region (2017-2022) & (K Pcs)
Table 80. Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Region (2023-2028) & (K Pcs)
Table 81. Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue by Region (2017-2022) & (US$ Million)
Table 82. Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue by Region (2023-2028) & (US$ Million)
Table 83. Latin America Antidiabetic SGLT-2 Inhibitor Sales by Type (2017-2022) & (K Pcs)
Table 84. Latin America Antidiabetic SGLT-2 Inhibitor Sales by Type (2023-2028) & (K Pcs)
Table 85. Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Type (2017-2022) & (US$ Million)
Table 86. Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Type (2023-2028) & (US$ Million)
Table 87. Latin America Antidiabetic SGLT-2 Inhibitor Sales by Application (2017-2022) & (K Pcs)
Table 88. Latin America Antidiabetic SGLT-2 Inhibitor Sales by Application (2023-2028) & (K Pcs)
Table 89. Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Application (2017-2022) & (US$ Million)
Table 90. Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Application (2023-2028) & (US$ Million)
Table 91. Latin America Antidiabetic SGLT-2 Inhibitor Sales by Country (2017-2022) & (K Pcs)
Table 92. Latin America Antidiabetic SGLT-2 Inhibitor Sales by Country (2023-2028) & (K Pcs)
Table 93. Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Country (2017-2022) & (US$ Million)
Table 94. Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Country (2023-2028) & (US$ Million)
Table 95. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Type (2017-2022) & (K Pcs)
Table 96. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Type (2023-2028) & (K Pcs)
Table 97. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue by Type (2017-2022) & (US$ Million)
Table 98. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue by Type (2023-2028) & (US$ Million)
Table 99. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Application (2017-2022) & (K Pcs)
Table 100. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Application (2023-2028) & (K Pcs)
Table 101. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue by Application (2017-2022) & (US$ Million)
Table 102. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue by Application (2023-2028) & (US$ Million)
Table 103. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Country (2017-2022) & (K Pcs)
Table 104. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Country (2023-2028) & (K Pcs)
Table 105. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue by Country (2017-2022) & (US$ Million)
Table 106. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue by Country (2023-2028) & (US$ Million)
Table 107. Pfizer Corporation Information
Table 108. Pfizer Description and Major Businesses
Table 109. Pfizer Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 110. Pfizer Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Pfizer Recent Developments
Table 112. AstraZeneca Corporation Information
Table 113. AstraZeneca Description and Major Businesses
Table 114. AstraZeneca Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 115. AstraZeneca Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. AstraZeneca Recent Developments
Table 117. Johnson & Johnson Corporation Information
Table 118. Johnson & Johnson Description and Major Businesses
Table 119. Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 120. Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Johnson & Johnson Recent Developments
Table 122. GlaxoSmithKline Corporation Information
Table 123. GlaxoSmithKline Description and Major Businesses
Table 124. GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 125. GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. GlaxoSmithKline Recent Developments
Table 127. Merck & Co Corporation Information
Table 128. Merck & Co Description and Major Businesses
Table 129. Merck & Co Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 130. Merck & Co Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Merck & Co Recent Developments
Table 132. Eli Lilly Corporation Information
Table 133. Eli Lilly Description and Major Businesses
Table 134. Eli Lilly Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 135. Eli Lilly Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Eli Lilly Recent Developments
Table 137. Sanofi Corporation Information
Table 138. Sanofi Description and Major Businesses
Table 139. Sanofi Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 140. Sanofi Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Sanofi Recent Developments
Table 142. Takeda Pharmaceuticals Corporation Information
Table 143. Takeda Pharmaceuticals Description and Major Businesses
Table 144. Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 145. Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Takeda Pharmaceuticals Recent Developments
Table 147. Novo Nordisk Corporation Information
Table 148. Novo Nordisk Description and Major Businesses
Table 149. Novo Nordisk Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 150. Novo Nordisk Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Novo Nordisk Recent Developments
Table 152. Servier Laboratories Corporation Information
Table 153. Servier Laboratories Description and Major Businesses
Table 154. Servier Laboratories Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 155. Servier Laboratories Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Servier Laboratories Recent Developments
Table 157. Boehringer Ingelheim Corporation Information
Table 158. Boehringer Ingelheim Description and Major Businesses
Table 159. Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 160. Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. Boehringer Ingelheim Recent Developments
Table 162. Bristol-Myers Squibb Corporation Information
Table 163. Bristol-Myers Squibb Description and Major Businesses
Table 164. Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 165. Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Product Model Numbers, Pictures, Descriptions and Specifications
Table 166. Bristol-Myers Squibb Recent Developments
Table 167. Key Raw Materials Lists
Table 168. Raw Materials Key Suppliers Lists
Table 169. Antidiabetic SGLT-2 Inhibitor Distributors List
Table 170. Antidiabetic SGLT-2 Inhibitor Customers List
Table 171. Antidiabetic SGLT-2 Inhibitor Market Trends
Table 172. Antidiabetic SGLT-2 Inhibitor Market Drivers
Table 173. Antidiabetic SGLT-2 Inhibitor Market Challenges
Table 174. Antidiabetic SGLT-2 Inhibitor Market Restraints
Table 175. Research Programs/Design for This Report
Table 176. Key Data Information from Secondary Sources
Table 177. Key Data Information from Primary Sources
List of Figures
Figure 1. Antidiabetic SGLT-2 Inhibitor Product Picture
Figure 3. Global Antidiabetic SGLT-2 Inhibitor Market Share by Type in 2021 & 2028
Figure 3. Canagliflozin Product Picture
Figure 4. Empagliflozin Product Picture
Figure 5. Dapagliflozin Product Picture
Figure 6. Other Product Picture
Figure 7. Global Antidiabetic SGLT-2 Inhibitor Market Share by Application in 2021 & 2028
Figure 8. Hospitals
Figure 9. Clinics
Figure 10. Other
Figure 11. Antidiabetic SGLT-2 Inhibitor Report Years Considered
Figure 12. Global Antidiabetic SGLT-2 Inhibitor Sales 2017-2028 (K Pcs)
Figure 13. Global Antidiabetic SGLT-2 Inhibitor Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Antidiabetic SGLT-2 Inhibitor Revenue 2017-2028 (US$ Million)
Figure 15. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 16. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region (2017-2022)
Figure 17. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region (2023-2028)
Figure 18. North America Antidiabetic SGLT-2 Inhibitor Sales YoY (2017-2028) & (K Pcs)
Figure 19. North America Antidiabetic SGLT-2 Inhibitor Revenue YoY (2017-2028) & (US$ Million)
Figure 20. Europe Antidiabetic SGLT-2 Inhibitor Sales YoY (2017-2028) & (K Pcs)
Figure 21. Europe Antidiabetic SGLT-2 Inhibitor R

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Metformin Hydrochloride Market Research Report 2024

Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 104

Metformin hydrochloride is The raw material of finished product metformin hydrochloride drugs. That is The API metformin hydrochloride. Metformin Hydrochloride finished product is an oral antihyperglycemic drug used in The management of type 2-diabetes. Metformin hydrochloride (N, N-dimethylimidodicarbonimidic diamide hydrochloride) is not chemically or pharmacologically related to any other classes of oral antihyperglycemic agents. Metformin hydrochloride is a white to off-white crystall......

Global Antidiabetic Sulphonylureas Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 112

Market Overview of Global Antidiabetic Sulphonylureas market: According to our latest research, the global Antidiabetic Sulphonylureas market looks promising in the next 5 years. As of 2022, the global Antidiabetic Sulphonylureas market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of t......

Global Insulin Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 101

According to our LPI (LP Information) latest study, the global Insulin market size was valued at US$ million in 2023. With growing demand in downstream market, the Insulin is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Insulin market. Insulin are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization......

Global Insulin API Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 116

According to our LPI (LP Information) latest study, the global Insulin API market size was valued at US$ 1707.6 million in 2023. With growing demand in downstream market, the Insulin API is forecast to a readjusted size of US$ 2101.4 million by 2030 with a CAGR of 3.0% during review period. The research report highlights the growth potential of the global Insulin API market. Insulin API are expected to show stable growth in the future market. However, product differentiation, reducing co......

Global Glucagon Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 101

According to our LPI (LP Information) latest study, the global Glucagon market size was valued at US$ 543.9 million in 2023. With growing demand in downstream market, the Glucagon is forecast to a readjusted size of US$ 835.7 million by 2030 with a CAGR of 6.3% during review period. The research report highlights the growth potential of the global Glucagon market. Glucagon are expected to show stable growth in the future market. However, product differentiation, reducing costs, and suppl......

Global Acarbose Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 95

According to our LPI (LP Information) latest study, the global Acarbose market size was valued at US$ 135.8 million in 2023. With growing demand in downstream market, the Acarbose is forecast to a readjusted size of US$ 165.9 million by 2030 with a CAGR of 2.9% during review period. The research report highlights the growth potential of the global Acarbose market. Acarbose are expected to show stable growth in the future market. However, product differentiation, reducing costs, and suppl......

Global Insulin Glargine Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 77

According to our LPI (LP Information) latest study, the global Insulin Glargine market size was valued at US$ 6562.1 million in 2023. With growing demand in downstream market, the Insulin Glargine is forecast to a readjusted size of US$ 8722.5 million by 2030 with a CAGR of 4.1% during review period. The research report highlights the growth potential of the global Insulin Glargine market. Insulin Glargine are expected to show stable growth in the future market. However, product differen......

Global Liraglutide Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 103

According to our LPI (LP Information) latest study, the global Liraglutide market size was valued at US$ million in 2023. With growing demand in downstream market, the Liraglutide is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Liraglutide market. Liraglutide are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply ch......

Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 96

According to our LPI (LP Information) latest study, the global Glucagon Like Peptide-1 (GLP-1) Agonists market size was valued at US$ 8624.4 million in 2023. With growing demand in downstream market, the Glucagon Like Peptide-1 (GLP-1) Agonists is forecast to a readjusted size of US$ 21310 million by 2030 with a CAGR of 13.8% during review period. The research report highlights the growth potential of the global Glucagon Like Peptide-1 (GLP-1) Agonists market. Glucagon Like Peptide-1 (GL......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs